Precipio (NASDAQ:PRPO – Get Free Report) and SBC Medical Group (NASDAQ:SBC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Earnings & Valuation
This table compares Precipio and SBC Medical Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 2.03 | -$360,000.00 | ($0.64) | -42.55 |
| SBC Medical Group | $175.17 million | 2.67 | $50.99 million | $0.47 | 9.66 |
Risk & Volatility
Precipio has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Profitability
This table compares Precipio and SBC Medical Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -4.47% | -8.49% | -5.75% |
| SBC Medical Group | 27.99% | 18.47% | 13.10% |
Institutional and Insider Ownership
10.4% of Precipio shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 16.6% of Precipio shares are held by company insiders. Comparatively, 81.7% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Precipio and SBC Medical Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| SBC Medical Group | 1 | 0 | 2 | 0 | 2.33 |
SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 87.22%. Given SBC Medical Group’s stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Precipio.
Summary
SBC Medical Group beats Precipio on 13 of the 14 factors compared between the two stocks.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About SBC Medical Group
SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
